Fairvalue-Calculator Fairvalue-Calculator
EN DE

JETEMA, Co (216080) Fair Value & Analysis

Healthcare · KR · Market cap 174B KRW

Price4,530 KRW
Fair Value8,215 KRW
Upside+81.3%
Quality95/100
Evidence: Low Range 6,161 KRW – 10,268 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

JETEMA, Co (216080) currently trades at 4,530 KRW, while our model-based Fair Value estimate is 8,215 KRW — implying the stock looks roughly 81.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers clostridium botulinum toxins, fillers, lifting threads for medical treatment, elastin and collagen stimulate solution under Ecolla, and healthy skin care under vitten brand names. The company also provides skin care hyaluronic acid masks. JETEMA, Co., Ltd. was founded in 2009 and is headquartered in Wonju-si, South Korea.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -61% EssilorLuxottica Société anonyme (ESLOF) -44% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -5% Becton, Dickinson and Company (BDX) -16% Alcon Inc (ALC) -44%

Frequently asked questions

Is JETEMA, Co (216080) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 8,215 KRW versus a price of 4,530 KRW — about +81% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 216080?
Our 21-model fair value for JETEMA, Co is 8,215 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 4,530 KRW.
What is the quality score of 216080?
JETEMA, Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.